Chemomab Therapeutics is a clinical-stage biotech company developing CM-101, a humanized monoclonal antibody that neutralizes the soluble protein CCL24, which drives inflammation and fibrosis in diseases such as primary sclerosing cholangitis and liver fibrosis. The company targets fibro-inflammatory-related diseases with high unmet medical needs, aiming to improve patient outcomes by interrupting the pathological processes that lead to excessive tissue scarring.
Funding
Funding not disclosed
Founders
Product
Problem
Fibro-inflammatory diseases, such as primary sclerosing cholangitis and liver fibrosis, involve a destructive cycle of inflammation and excessive tissue scarring, leading to organ damage and impaired function. Current treatments often fail to adequately address the underlying mechanisms driving this cycle, resulting in limited efficacy and poor patient outcomes. There is a significant unmet need for therapies that can effectively interrupt the pathological processes leading to fibrosis.
Solution
Chemomab Therapeutics is developing CM-101, a first-in-class humanized monoclonal antibody designed to neutralize CCL24, a soluble protein that plays a key role in promoting inflammation and fibrosis. By binding to and neutralizing CCL24, CM-101 aims to interrupt the fibro-inflammatory vicious cycle, addressing the underlying cause of tissue damage in fibro-inflammatory diseases. CM-101 has demonstrated efficacy in preclinical models of liver, skin, and lung fibrosis, and has shown encouraging clinical activity in patients with primary sclerosing cholangitis (PSC) and metabolic-associated steatohepatitis (MASH). The therapeutic platform targets the dual pathway of CCL24, which includes both the recruitment of immune cells to damaged tissue and the direct activation of tissue fibroblasts.
Target Audience
The primary target audience includes patients suffering from fibro-inflammatory diseases with high unmet medical needs, such as primary sclerosing cholangitis, liver fibrosis, and systemic sclerosis, as well as the physicians who treat them.
Features
- CM-101: A humanized monoclonal antibody that selectively binds to and neutralizes CCL24 activity.
- Interrupts the CCL24-mediated dual pathway of inflammation and fibrosis.
- Demonstrated efficacy in preclinical models of liver, skin, and lung fibrosis.
- Positive topline data from a Phase 2 trial in patients with primary sclerosing cholangitis (PSC).
- Encouraging biomarker data from a Phase 2a trial in patients with metabolic-associated steatohepatitis (MASH).
- Potential for intravenous (IV) and subcutaneous (SC) formulations.